Waldenstrom Macroglobulinemia Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
B
Recruiting
  • B-cell Malignancy, Low-grade
  • +4 more
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai JiaoTong University School of Medicine
2022-04-05
Apr 5, 2022
F
Recruiting
  • Waldenstrom Macroglobulinemia
    • Badalona, Barcelona, Spain
    • +17 more
    2022-04-06
    Apr 6, 2022
    N
    Recruiting
    • Lymphoplasmacytic Lymphoma
    • Waldenstrom Macroglobulinemia
    • Centralia, Illinois
    • +72 more
    2022-04-05
    Apr 5, 2022
    L
    Available
    • Leukemia, Lymphocytic, Chronic, B-Cell
    • +4 more
    • Stanford, California
    • +19 more
    2022-04-05
    Apr 5, 2022
    D
    Active, not recruiting
    • Waldenstrom Macroglobulinemia
    • MYD88 Gene Mutation
    • Boston, Massachusetts
    • +1 more
    2022-04-01
    Apr 1, 2022
    N
    Recruiting
    • Waldenstrom Macroglobulinemia
    • +4 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center, 9000 Rockville Pi
      2022-03-31
      Mar 31, 2022
      Q
      Recruiting
      • Follicular Lymphoma
      • +7 more
      • Louisville, Kentucky
      • +4 more
      2022-03-11
      Mar 11, 2022
      C
      Recruiting
      • Waldenstrom Macroglobulinemia
      • Salzburg, Austria
      • +16 more
      2022-03-11
      Mar 11, 2022
      J
      Active, not recruiting
      • Waldenstrom Macroglobulinemia
      • Chiba, Japan
      • +8 more
      2022-03-24
      Mar 24, 2022
      J
      Active, not recruiting
      • Waldenstrom Macroglobulinemia
      • Changchun, China
      • +5 more
      2022-03-24
      Mar 24, 2022
      J
      Enrolling by invitation
      • Chronic Lymphocytic Leukemia
      • +6 more
      • Duarte, California
      • +165 more
      2022-03-24
      Mar 24, 2022
      J
      Recruiting
      • Waldenstrom Macroglobulinemia
      • DASATINIB
      • Boston, Massachusetts
        Dana Farber Cancer Institute
      2022-03-22
      Mar 22, 2022
      U
      Active, not recruiting
      • Non Hodgkin Lymphoma
      • +8 more
      • Miami, Florida
      • +2 more
      2022-03-08
      Mar 8, 2022
      B
      Recruiting
      • B-cell Malignancy
      • +4 more
      • Louisville, Kentucky
      • +4 more
      2022-03-22
      Mar 22, 2022
      T
      Active, not recruiting
      • Waldenstrom Macroglobulinemia
      • Washington, District of Columbia
      • +3 more
      2022-03-22
      Mar 22, 2022
      R
      Recruiting
      • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
      • +36 more
      • Buffalo, New York
        Roswell Park Cancer Institute
      2022-03-17
      Mar 17, 2022
      E
      Recruiting
      • Leukemia, Lymphocytic, Chronic, B-Cell
      • +6 more
      • Miami, Florida
      • +4 more
      2022-03-07
      Mar 7, 2022
      D
      Recruiting
      • Monoclonal Gammopathy of Undetermined Significance (MGUS)
      • +8 more
        • Boston, Massachusetts
        • +1 more
        2022-03-15
        Mar 15, 2022
        S
        Recruiting
        • Waldenstrom Macroglobulinemia
        • Boston, Massachusetts
          Dana Farber Cancer Institute
        2022-03-01
        Mar 1, 2022
        A
        Active, not recruiting
        • Lymphoma, B-Cell
        • +8 more
        • Scottsdale, Arizona
        • +9 more
        2022-03-10
        Mar 10, 2022
        H
        Recruiting
        • CLL/SLL
        • +8 more
        • Atlanta, Georgia
        • +3 more
        2022-02-24
        Feb 24, 2022
        U
        Not yet recruiting
        • Waldenstrom Macroglobulinemia
        • Venetoclax; Rituximab
        • DRC
        • (no location specified)
        2022-03-09
        Mar 9, 2022
        B
        Recruiting
        • Mantle Cell Lymphoma
        • +9 more
        • L-Bcl-2 antisense oligonucleotide
        • Augusta, Georgia
        • +2 more
        2022-03-08
        Mar 8, 2022
        C
        Active, not recruiting
        • Waldenstrom Macroglobulinemia
        • Ibrutinib / Bortezomib / Rituximab
        • Berlin, Germany
        • +14 more
        2022-03-07
        Mar 7, 2022